One Turn Open the globe →Globe →

The story so far · 2 days, November 15 to 16, 2026

FDA rejects China's lung cancer drug ivonescimab

One Turn followed this story across 2 editions, from Washington, United States on November 15, 2026. Newest first.

Akeso is a Hong Kong-listed Chinese biotech company.

Open the latest on the 3D globe →

Day by day

  1. US FDA rejects China lung cancer drug
  2. FDA rejects China's lung cancer drug ivonescimab

Every installment

Monday, November 16, 2026 · Day 2 · Health · Hong Kong · China

FDA rejects China's lung cancer drug ivonescimab

The US FDA rejected Akeso's cancer drug ivonescimab. Akeso shares fell as much as 31.8% in Hong Kong. The drug had become a symbol of China's rise in drug development.

Why it matters: The decision is a setback for Chinese drugmakers seeking US approval.

Sources: South China Morning Post, The Straits Times · See it on the globe

Sunday, November 15, 2026 · Day 1 · Health · Washington, United States · United States of America

US FDA rejects China lung cancer drug

The FDA rejected ivonescimab, a closely watched lung cancer drug from China. It had become a symbol of China's rise in drug development.

Why it matters: It affects Chinese drugmakers' hopes in the US market.

Sources: The Straits Times · See it on the globe

Where

More running stories →